Discovery of a Selective pan-FGFR Inhibitor Approved for Treatment of Cholangiocarcinoma

Please copy the URL and add it into your RSS Feed Reader.

Facebook Linkedin Weibo

Download PDF

Synfacts 2023; 19(06): 0615
DOI: 10.1055/s-0042-1752682

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Danica A. Rankic (Pfizer)

futibatinib - pan-FGFR inhibitor - covalent drug - cholangiocarcinoma - hit-to-lead

Article published online:
11 May 2023

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany